ConductScience.org, home

Paper34835459

Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.

Ezquerra-Aznárez JM and 2 others. Microorganisms, 2021. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs. Papers, record 34835459. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34835459

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.
PubMed
Journal
Microorganisms
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.21
iCite
Revised in PubMed
2021-11-30
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ezquerra-Aznárez JMJosé Manuel
2Almeida da Silva PEPedro Ehttps://orcid.org/0000-0003-1666-1295
3Aínsa JAJosé Ahttps://orcid.org/0000-0003-2076-844X

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
FPU18/03873 to JMEAMinisterio de Universidades (Spain)PubMed
Capes-PrInt Program, - Financing Code 001 to PEASCoordenação de Aperfeicoamento de Pessoal de Nível SuperiorPubMed

Source PubMed

Download CSV of grants

References101

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129649664Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48.Int J Parasitol Drugs Drug Resist2018https://conductscience.org/library/papers/29649664PubMed
322589723Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis.PLoS Pathog2012https://conductscience.org/library/papers/22589723PubMed
4464563Avermectins, new family of potent anthelmintic agents: efficacy of the B1a component.Antimicrob Agents Chemother1979https://conductscience.org/library/papers/464563PubMed
528167557Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/28167557PubMed
623507275Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis.Antimicrob Agents Chemother2013https://conductscience.org/library/papers/23507275PubMed
722877082Review of pyronaridine anti-malarial properties and product characteristics.Malar J2012https://conductscience.org/library/papers/22877082PubMed
810707260Antituberculosis activity of certain antifungal and antihelmintic drugs.Tuber Lung Dis1999https://conductscience.org/library/papers/10707260PubMed
921393225Nitroreductase (GlNR1) increases susceptibility of Giardia lamblia and Escherichia coli to nitro drugs.J Antimicrob Chemother2011https://conductscience.org/library/papers/21393225PubMed
1030205975The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase.Tuberculosis (Edinb)2018https://conductscience.org/library/papers/30205975PubMed
1125079790Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis.PLoS Negl Trop Dis2014https://conductscience.org/library/papers/25079790PubMed
1218159536Where are all the new antibiotics? The new antibiotic paradox.Can J Infect Dis Med Microbiol2005https://conductscience.org/library/papers/18159536PubMed
136893469Ivermectin, a new broad-spectrum antiparasitic agent.J Med Chem1980https://conductscience.org/library/papers/6893469PubMed
1412019076Mefloquine and new related compounds target the F(0) complex of the F(0)F(1) H(+)-ATPase of Streptococcus pneumoniae.Antimicrob Agents Chemother2002https://conductscience.org/library/papers/12019076PubMed
1527338184Benzimidazole resistance in helminths: From problem to diagnosis.Acta Trop2016https://conductscience.org/library/papers/27338184PubMed
1616143463In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv.FEMS Microbiol Lett2005https://conductscience.org/library/papers/16143463PubMed
1718491971Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency.J Infect Dis2008https://conductscience.org/library/papers/18491971PubMed
1829987141Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29987141PubMed
1929603892Niclosamide, a Drug with Many (Re)purposes.ChemMedChem2018https://conductscience.org/library/papers/29603892PubMed
2024736743A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis.PLoS One2014https://conductscience.org/library/papers/24736743PubMed
2116569295Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics.Parasitology2005https://conductscience.org/library/papers/16569295PubMed

See all 101 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
37110480Mycobacterium tuberculosis Infection: Control and Treatment.Microorganisms2023https://conductscience.org/library/papers/37110480PubMed
37020538Immunomodulation resulting of helminth infection could be an opportunity for immunization against tuberculosis and mucosal pathogens.Front Immunol2023https://conductscience.org/library/papers/37020538PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ABCG29429PubTator's text mininghttps://conductscience.org/library/genes/9429

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34835459

GET https://conductscience.org/api/papers/v1/34835459/references?page=2